Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
Jevalikar G, Mithal A, Singh A, Sharma R, Farooqui KJ, Mahendru S, Dewan A, Budhiraja S
Scientific reports · 44 citations
How it was studied
- Design
- Cohort study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2021-03-18 · Sci Rep · vol. 11 · issue 1 · p. 6258
- Publisher
- Nature Portfolio
- Cited
- 105 citations · more than 100% of similar papers · 14.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 37 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · Vitamin C and Antioxidants Research
- Keywords
- Medicine, Vitamin D and neurology, Internal medicine, Coronavirus disease 2019 (COVID-19), Gastroenterology, vitamin D deficiency, Cholecalciferol, Prospective cohort study, Severity of illness, Observational study, Ferritin, Disease
- MeSH
- humans, vitamin d deficiency, cholecalciferol, parathyroid hormone, vitamin d, severity of illness index, prevalence, prospective studies, cross-sectional studies, adolescent, adult, aged, aged, 80 and over, middle aged, child, india, female, male, young adult, covid-19
8 authors
From IN
- Ganesh Jevalikar · correspondingMax Healthcare
- Ambrish MithalMax Healthcare
- Anshu SinghMax Healthcare
- Rutuja SharmaMax Healthcare
- Khalid Jamal FarooquiMax Healthcare
- Shama MahendruMax Healthcare
Abstract
Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.